Prognostic significance of lncRNA AP004608.1 in prostate cancer

Wei Li; Runze Zhou; Bo Sun; Xin Jin; Yuan Chen; Xuefen Xu

doi:10.3389/fonc.2022.1017635

Prognostic significance of lncRNA AP004608.1 in prostate cancer

Front Oncol. 2022 Sep 29:12:1017635. doi: 10.3389/fonc.2022.1017635. eCollection 2022.

Authors

Wei Li^{1

2}, Runze Zhou², Bo Sun², Xin Jin³, Yuan Chen⁴, Xuefen Xu⁴

Affiliations

¹ Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
² Institute of Traditional Chinese medicine (TCM)-Related Comorbid Depression, School of Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
³ Department of Pharmacy, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
⁴ Department of Pharmacology, School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

Abstract

This study aimed to screen and determine the value of AP004608.1 expression as a biomarker for Prostate cancer (PCa) survival. We investigated the expression and prognosis of AP004608.1 through bioinformatics analysis. Low AP004608.1 expression predicted favorable Overall survival (OS) and Progression-free survival (PFS) in PCa patients, according to the Cancer Genome Atlas (TCGA) database. Cox regression demonstrated that low AP004608.1 expression were in-dependent biomarkers for OS. Moreover, Gene Expression Omnibus (GEO) database was utilized to verify the prognostic role of AP004608.1 in PCa, and the similar results were reached. A meta-analysis revealed that low AP004608.1 expression was closely relevant to better OS. AP004608.1 could constitute a promising prognostic biomarker, and probably plays an important role in PCa.

Keywords: AP004608.1; meta-analysis; prognostic; prostate cancer; survival.